{
  "docId": "019de075-12bd-74a7-bc75-4587e4948a57",
  "docSlug": "9c54f748d4238e6a3a690a4101a45e99",
  "documentTitle": "Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 50,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The chart uses a conceptual scatter plot to contrast current SOC with a future target state, emphasizing the need for higher efficacy and better convenience.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-12bd-74a7-bc75-4587e4948a57/7",
  "deckHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57",
  "deckJsonHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57.json",
  "deckAnchorHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.8,
        "x": 0.08,
        "y": 0.25
      },
      "kind": "chart",
      "text": "UC Maintenance Remission Rates (%) vs Maintenance dosing frequency (weeks)",
      "attrs": null,
      "subkind": "scatter",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0fa0a85f-e074-4d7a-a188-b90ce63b51ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "Summary data for select agents that randomize patients post response to induction; data from labels, company reports. Vedolizumab approved in US as Q8W IV – Q2W SC approval pending following CRL in 2019. TL1A maintenance data not available. Orals not shown (pbo-adj maintenance remission rates): Jaks - tofacitinib (27%), upadacitinib (30% 15mg, 40% 30mg); S1Ps: ozanimod (19%); etrasimod (25% - P3 Treat-through design).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f9730221-7044-41ec-b77a-5de5a491c15a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Despite advances, new approaches are needed to break the efficacy ceiling and improve convenience of biologics",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96ade3d9-c370-4e76-bf7f-8ceef337635b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gap-analysis",
      "slug": null,
      "matchId": "30a068de-571d-4477-aa03-57977b73fb0f",
      "evidence": "Visual contrast between current SOC cluster and future target state",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 8,
      "from": 5,
      "beatId": "882cdb54-6c52-42e8-a2ed-ebb98d1061ae",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Problem & Complication",
      "beatSlug": "consultants-gambit-problem-complication",
      "evidence": "Slides 5-8 highlight the limitations of current biologics and the need for new approaches.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}